Biomarin Pharmaceutical Inc (BMRN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Biomarin Pharmaceutical reported revenue of $3.22B, up 12.9% from $2.85B the year before. Net income was $348.9M (a 10.8% net margin), or $1.80 per diluted share. Gross margin was 77.7% and operating margin was 12.7%. Operating activities generated $828.0M of cash, leaving $725.0M of free cash flow. At fiscal year end, Biomarin Pharmaceutical held $7.59B in total assets against $1.51B in total liabilities, including $1.31B of cash and equivalents.
Open the full interactive Biomarin Pharmaceutical financials → Quarterly statements, key ratios, valuation history and price charts.
Biomarin Pharmaceutical Key Stats
| Share Price | $54.38 |
|---|---|
| Market Cap | $10.58B |
| P/E Ratio | 30.2 |
| Revenue YoY Growth | +12.9% |
| 52-Week Range | $49.67 – $70.24 |
| Shares Outstanding | 193.4 million (basic, 2026 Q2) |
Biomarin Pharmaceutical Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.86B | $1.85B | $2.10B | $2.42B | $2.85B | $3.22B |
| Cost of Goods Sold | $1.90B | $1.93B | $1.95B | $2.26B | $2.37B | $2.81B |
| Gross Profit | $1.34B | $1.38B | $1.61B | $1.90B | $2.27B | $2.50B |
| Operating Income | -$36.8M | -$82.3M | $149.6M | $158.1M | $484.2M | $409.5M |
| Pre-Tax Income | -$42.3M | -$75.3M | $149.6M | $188.6M | $541.8M | $482.5M |
| Income Tax | -$901.4M | -$11.3M | $8.0M | $20.9M | $114.9M | $133.6M |
| Net Income | $859.1M | -$64.1M | $141.6M | $167.6M | $426.9M | $348.9M |
| Diluted EPS | $4.53 | -$0.35 | $0.75 | $0.87 | $2.21 | $1.80 |
Biomarin Pharmaceutical Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $776.1M | $874.6M | $766.2M | $989.7M |
| Net Income | -$30.7M | -$46.6M | $105.5M | $44.8M |
| Diluted EPS | -$0.16 | -$0.24 | $0.54 | $0.23 |
Biomarin Pharmaceutical Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $649.2M | $587.3M | $724.5M | $755.1M | $942.8M | $1.31B |
| Current Assets | $2.34B | $2.27B | $2.75B | $2.96B | $3.23B | $3.95B |
| Total Assets | $5.85B | $6.00B | $6.38B | $6.84B | $6.99B | $7.59B |
| Current Liabilities | $492.5M | $539.8M | $588.9M | $1.18B | $607.0M | $759.0M |
| Total Long-Term Debt | $1.08B | $1.08B | $1.08B | $1.09B | $595.1M | $597.2M |
| Total Liabilities | $1.74B | $1.73B | $1.77B | $1.89B | $1.33B | $1.51B |
| Shareholders' Equity | $4.11B | $4.27B | $4.60B | $4.95B | $5.66B | $6.09B |
Biomarin Pharmaceutical Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $85.4M | $304.5M | $175.9M | $159.3M | $572.8M | $828.0M |
| Cash From Investing | -$53.6M | -$366.3M | -$20.0M | -$111.2M | $136.5M | -$414.2M |
| Cash From Financing | $181.1M | -$48,000 | -$18.6M | -$18.7M | -$526.4M | -$42.4M |
| Free Cash Flow | -$28.9M | $209.0M | $54.9M | $62.6M | $487.4M | $725.0M |
Figures from Biomarin Pharmaceutical's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Biomarin Pharmaceutical financials page for every line item.
Biomarin Pharmaceutical Company Profile
| Ticker | BMRN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Novato, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001048477 |
Frequently Asked Questions
What was Biomarin Pharmaceutical's revenue in fiscal 2025?
Biomarin Pharmaceutical (BMRN) reported revenue of $3.22B for fiscal 2025.
What is Biomarin Pharmaceutical's annual revenue history?
Biomarin Pharmaceutical's annual revenue by fiscal year: 2020: $1.86B; 2021: $1.85B; 2022: $2.10B; 2023: $2.42B; 2024: $2.85B; 2025: $3.22B.
What was Biomarin Pharmaceutical's net income in fiscal 2025?
Biomarin Pharmaceutical reported net income of $348.9M for fiscal 2025.
What was Biomarin Pharmaceutical's earnings per share (EPS) in fiscal 2025?
Biomarin Pharmaceutical's diluted EPS was $1.80 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Biomarin Pharmaceutical generate in fiscal 2025?
Biomarin Pharmaceutical generated $725.0M of free cash flow in fiscal 2025.
What was Biomarin Pharmaceutical's revenue last quarter?
In its most recent reported quarter (2026 Q2), Biomarin Pharmaceutical reported revenue of $989.7M.
How much debt does Biomarin Pharmaceutical have?
Biomarin Pharmaceutical reported $597.2M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Biomarin Pharmaceutical are outstanding?
Biomarin Pharmaceutical reported a weighted average of 193.4 million basic shares outstanding in 2026 Q2.
What is Biomarin Pharmaceutical's market cap?
Based on its latest closing price, Biomarin Pharmaceutical (BMRN) has a market capitalization of about $10.58B.
When does Biomarin Pharmaceutical's fiscal year end?
Biomarin Pharmaceutical's fiscal year end, as registered with the SEC, is December 31.
Where is Biomarin Pharmaceutical headquartered?
Biomarin Pharmaceutical lists its business address in Novato, California in its SEC filings.